{"id":"NCT03227861","sponsor":"Janssen Scientific Affairs, LLC","briefTitle":"A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care","officialTitle":"A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-na√Øve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-31","primaryCompletion":"2019-01-03","completion":"2019-09-04","firstPosted":"2017-07-24","resultsPosted":"2020-01-07","lastUpdate":"2025-02-04"},"enrollment":109,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1"],"interventions":[{"type":"DRUG","name":"DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC","otherNames":[]}],"arms":[{"label":"DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) fixed-dose combination (FDC) in a Test and Treat model of care in newly diagnosed human immunodeficiency virus (HIV-1)-infected, treatment-naive participants as determined by the proportion of virologic responders defined as having (HIV)-1 ribonucleic acid (RNA) lesser than 50 copies per milliliter (copies/mL) at Week 48.","primaryOutcome":{"measure":"Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Less Than (<) 50 Copies Per Milliliter (Copies/mL) (Virologic Response) at Week 48 Defined by Food and Drug Administration (FDA) Snapshot Approach","timeFrame":"Week 48","effectByArm":[{"arm":"D/C/F/TAF: Main Study","deltaMin":84.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["33999786","31879782"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":109},"commonTop":["Diarrhoea","Nausea","Weight Decreased","Vomiting","Hypertension"]}}